Clinical trialEPhase 1Unknown
Clinical Trial to Evaluate the Safety and Efficacy of IM96 CAR-T Cells Therapy in Patients With Advanced Digestive System Neoplasms
- Outcome
- Outcome unknown
- Phase
- EPhase 1
- Status
- Unknown
- Study type
- Interventional
- Start
- 10 March 2022
- Expected end
- 30 June 2024
- Enrollment
- 19 participants
- Sites
- 1
- Primary outcomes
- Incidence of Treatment Related adverse events (AEs)
- Sponsor
- Industry
- Results posted
- No
- Last update
- 18 March 2022
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This is a open-label, single center to determine the efficacy and safety of IM96 CAR-T cells in Patients With Advanced Digestive System Neoplasms